Follicular Lymphoma

• CLINICAL_TRIALS research · 2017-03-09
  Clinical Trial Update: Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

  Administrative update reporting procurement of follicular B cell lymphoma cells for potential use in future clinical trials.

• CLINICAL_TRIALS trial_result · 2017-03-03
  Clinical Trial Update: Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon [Phase 2]

  Phase 2 clinical trial evaluating high-dose therapy with stem cell support followed by Rituximab and alpha interferon for follicular lymphom…

• CLINICAL_TRIALS trial_result · 2017-02-28
  Clinical Trial Update: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy [Phase 1]

  Phase 1 trial evaluating CART19 therapy for B-cell hematologic malignancies including various lymphomas and leukemias that are refractory or…

• CLINICAL_TRIALS trial_result · 2017-02-28
  Clinical Trial Update: S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911

  A clinical trial update reporting on biological markers in patients with follicular lymphoma treated on SWOG trials SWOG-8809, SWOG-9800, an…

• CLINICAL_TRIALS trial_result · 2017-02-07
  Clinical Trial Update: Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab [Phase 2]

  A completed Phase 2 clinical trial studied rituximab and/or lenalidomide in patients with follicular lymphoma that is not refractory to ritu…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2017-01-30
  Clinical Trial Update: BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma [Phase 3]

  Phase 3 trial comparing BI 695500 to Rituxan as first-line treatment in low tumor burden follicular lymphoma was terminated with results pos…

• CLINICAL_TRIALS trial_result · 2017-01-27
  Clinical Trial Update: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating a conditioning regimen with Iodine-131 tositumomab plus etoposide and cyclophosphamide, followed by autolo…

• CLINICAL_TRIALS trial_result · 2016-12-23
  Clinical Trial Update: Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Phase 1]

  Phase 1 study evaluating a combination of bortezomib, rituximab, and yttrium-90 ibritumomab tiuxetan in relapsed or refractory low-grade, fo…

• CLINICAL_TRIALS trial_result · 2016-12-22
  Clinical Trial Update: A Phase II Study of Doxycycline in Relapsed NHL [Phase 2]

  Phase II trial of doxycycline in relapsed non-Hodgkin lymphoma was terminated and results were posted in 2016.

• CLINICAL_TRIALS trial_result · 2016-12-21
  Clinical Trial Update: Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma [Phase 1, Phase 2]

  Clinical trial update for idelalisib (GS-1101) in previously treated indolent non-Hodgkin's lymphoma, including follicular lymphoma, reporti…

• CLINICAL_TRIALS trial_result · 2016-12-06
  Clinical Trial Update: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma [Phase 1, Phase 2]

  Clinical trial update describing the evaluation of PCAR-119 Bridge Immunotherapy as a pre-transplant treatment for CD19-positive leukemias a…

• CLINICAL_TRIALS trial_result · 2016-12-01
  Clinical Trial Update: CD180 Overexpression in Follicular Lymphoma

  A clinical trial evaluating CD180 overexpression in follicular lymphoma has completed.

• CLINICAL_TRIALS trial_result · 2016-11-21
  Clinical Trial Update: Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) [Phase 2]

  Phase 2 trial assessing blood stem cell transplant with low-dose chemotherapy for relapsed follicular non-Hodgkin's lymphoma (BMT CTN 0701) …

• CLINICAL_TRIALS research · 2016-11-09
  Clinical Trial Update: Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis

  A single-center retrospective analysis of 237 patients with follicular lymphoma describing the various causes of death observed in this coho…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma [Phase 2]

  Phase 2 trial evaluating Rituximab (MabThera/Rituxan) in patients with non-bulky follicular non-Hodgkin's lymphoma has completed.

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma [Phase 1]

  Phase 1 pharmacokinetic study comparing subcutaneous and intravenous rituximab in patients with follicular lymphoma to assess absorption and…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma [Phase 2]

  A Phase 2 clinical trial of rituximab (MabThera/Rituxan) in follicular lymphoma has completed.

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

  An observational study of Rituximab (MabThera/Rituxan) in patients with follicular lymphoma has been terminated.

• CLINICAL_TRIALS trial_result · 2016-10-25
  Clinical Trial Update: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]

  Clinical trial update on CD19-targeted CAR-T cell therapy being tested in relapsed/refractory leukemias and lymphomas (Phase 1 and Phase 2).

• CLINICAL_TRIALS trial_result · 2016-10-24
  Clinical Trial Update: Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 trial of fludarabine, bortezomib (Velcade), and rituximab for relapsed or refractory follicular lymphoma has been terminated, with…

• CLINICAL_TRIALS research · 2016-10-07
  Clinical Trial Update: An Italian Experience on Grade 3b Follicular Lymphoma

  The document reports an Italian clinical trial experience related to Grade 3b Follicular Lymphoma, outlining observational findings and insi…

• CLINICAL_TRIALS research · 2016-10-05
  Clinical Trial Update: Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma [NA]

  The update investigates the clinical and prognostic relevance of sarcopenia in patients over 70 with diffuse large B-cell lymphoma, highligh…

• FDA approval · 2016-09-21
  FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)

  The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.

• CLINICAL_TRIALS trial_result · 2016-08-12
  Clinical Trial Update: A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma

  A clinical trial evaluating rituximab in combination with chemotherapy for relapsed/refractory follicular lymphoma has completed and results…

• CLINICAL_TRIALS withdrawal · 2016-08-11
  Clinical Trial Update: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/Phase 2 study of Rituximab, Romidepsin, and Lenalidomide for recurrent or refractory B-cell non-Hodgkin lymphoma has been withdraw…